Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_2
3
60%
Ph phase_1
1
20%
Ph phase_3
1
20%

Phase Distribution

1

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 23 (60.0%)
Phase 31 (20.0%)

Trials by Status

active_not_recruiting240%
completed360%

Recent Activity

2 active trials
Showing 5 of 5
active_not_recruitingphase_2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

NCT05909904
completedphase_3

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

NCT04164199
completedphase_2

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

NCT06010303
completedphase_1

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

NCT04640545
active_not_recruitingphase_2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

NCT05635708

Clinical Trials (5)

Showing 5 of 5 trials
NCT05909904Phase 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Active Not Recruiting
NCT04164199Phase 3

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Completed
NCT06010303Phase 2

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Completed
NCT04640545Phase 1

A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma

Completed
NCT05635708Phase 2

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Active Not Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5